Upstream Bio Inc [UPB] stock prices are up 15.78% to $13.35 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The UPB shares have gain 20.92% over the last week, with a monthly amount glided 17.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On November 05, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $75 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $38 on November 05, 2024.
The stock price of Upstream Bio Inc [UPB] has been fluctuating between $5.14 and $29.46 over the past year. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Upstream Bio Inc [NASDAQ: UPB] shares were valued at $13.35 at the most recent close of the market. An investor can expect a potential return of 461.8% based on the average UPB price forecast.
Analyzing the UPB fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -41.27%, Pretax Profit Margin comes in at -34.49%, and Net Profit Margin reading is -34.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.52 and Total Capital is -0.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.99 points at the first support level, and at 10.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.15, and for the 2nd resistance point, it is at 14.96.
Ratios To Look Out For
It’s worth pointing out that Upstream Bio Inc [NASDAQ:UPB]’s Current Ratio is 47.43. On the other hand, the Quick Ratio is 47.43, and the Cash Ratio is 7.45.
Transactions by insiders
Recent insider trading involved Chimovits Erez, Director, that happened on Oct 15 ’24 when 0.82 million shares were purchased. Director, ORBIMED ADVISORS LLC completed a deal on Oct 15 ’24 to buy 0.82 million shares. Meanwhile, 10% Owner AI Upstream LLC bought 1.18 million shares on Oct 15 ’24.
